Ardent Health Faces Class Action Lawsuit Amid $43 Million Revenue Drop in Q3 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Ardent Health, alleging securities fraud by the company and its executives, with investors needing to apply by March 9, 2026, to become Lead Plaintiff to protect their interests.
- Significant Revenue Decline: Ardent reported a $43 million decrease in Q3 2025 revenue, primarily due to revised assessments of accounts receivable collectability following the implementation of a new revenue accounting system, which negatively impacts the company's financial stability.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to between $53 million and $55 million, a reduction of approximately 9.6% from the previous range of $57.5 million to $62.5 million, indicating ongoing challenges due to persistent industry-wide cost pressures.
- Stock Price Plummet: Following the revenue decline and EBITDA guidance cut, Ardent's stock price fell by $4.75, or 33.81%, closing at $9.30 per share on November 13, 2025, reflecting the market's pessimistic outlook on the company's future.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDT is 13.96 USD with a low forecast of 10.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 8.860
Low
10.00
Averages
13.96
High
17.00
Current: 8.860
Low
10.00
Averages
13.96
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
